Nifty
Sensex
:
:
17196.70
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)

Pharmaceuticals & Drugs - Global

Rating :
54/99

BSE: 500087 | NSE: CIPLA

912.05
03-Dec-2021
  • Open
  • High
  • Low
  • Previous Close
  •  930.00
  •  930.00
  •  908.30
  •  921.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2388529
  •  21820.19
  •  1005.00
  •  738.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 73,566.86
  • 28.43
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 73,921.19
  • 0.55%
  • 3.79

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.12%
  • 0.71%
  • 16.01%
  • FII
  • DII
  • Others
  • 24.8%
  • 20.58%
  • 1.78%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.56
  • 5.89
  • 5.40

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.69
  • 11.07
  • 7.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.80
  • 18.99
  • 16.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.25
  • 33.22
  • 30.03

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 3.37
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.01
  • 15.85
  • 14.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
5,519.80
5,038.29
9.56%
5,504.35
4,346.16
26.65%
4,606.45
4,376.19
5.26%
5,168.69
4,371.00
18.25%
Expenses
4,293.60
3,861.72
11.18%
4,158.46
3,297.42
26.11%
3,810.21
3,742.67
1.80%
3,937.81
3,612.67
9.00%
EBITDA
1,226.20
1,176.57
4.22%
1,345.89
1,048.74
28.33%
796.24
633.52
25.69%
1,230.88
758.33
62.31%
EBIDTM
22.21%
23.35%
24.45%
24.13%
17.29%
14.48%
23.81%
17.35%
Other Income
60.67
53.47
13.47%
64.93
65.45
-0.79%
60.13
93.18
-35.47%
86.94
72.13
20.53%
Interest
38.00
39.33
-3.38%
29.57
46.00
-35.72%
27.45
53.00
-48.21%
47.92
46.17
3.79%
Depreciation
253.06
265.06
-4.53%
261.11
268.98
-2.93%
285.19
345.80
-17.53%
248.43
277.89
-10.60%
PBT
995.81
925.65
7.58%
995.52
799.21
24.56%
543.73
327.90
65.82%
1,021.47
506.40
101.71%
Tax
283.81
263.80
7.59%
283.72
227.78
24.56%
128.22
85.59
49.81%
268.96
152.82
76.00%
PAT
712.00
661.85
7.58%
711.80
571.43
24.56%
415.51
242.31
71.48%
752.51
353.58
112.83%
PATM
12.90%
13.14%
12.93%
13.15%
9.02%
5.54%
14.56%
8.09%
EPS
8.82
8.25
6.91%
8.86
7.17
23.57%
5.13
3.05
68.20%
9.28
4.35
113.33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
20,799.29
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
Net Sales Growth
14.71%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
 
Cost Of Goods Sold
8,021.43
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
Gross Profit
12,777.86
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
GP Margin
61.43%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
Total Expenditure
16,200.08
14,975.48
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
Power & Fuel Cost
-
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
% Of Sales
-
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
Employee Cost
-
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
% Of Sales
-
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
Manufacturing Exp.
-
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
541.58
583.18
% Of Sales
-
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
6.54%
8.31%
General & Admin Exp.
-
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
% Of Sales
-
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
Selling & Distn. Exp.
-
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
% Of Sales
-
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
Miscellaneous Exp.
-
572.54
766.82
855.40
968.98
645.54
657.29
497.67
441.10
355.12
467.61
% Of Sales
-
2.99%
4.48%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
4.29%
2.76%
EBITDA
4,599.21
4,184.11
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
EBITDA Margin
22.11%
21.84%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
Other Income
272.67
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
Interest
142.94
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
Depreciation
1,047.79
1,003.12
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
PBT
3,556.53
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
Tax
964.71
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
Tax Rate
27.13%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
PAT
2,591.82
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
PAT before Minority Interest
2,597.24
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
Minority Interest
5.42
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
PAT Margin
12.46%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
PAT Growth
41.69%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
 
EPS
32.30
30.13
19.87
19.25
17.61
12.63
17.10
15.03
17.46
19.33
14.22

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
Share Capital
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
Total Reserves
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
Non-Current Liabilities
1,660.06
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
Secured Loans
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
Unsecured Loans
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
Long Term Provisions
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
Current Liabilities
4,591.55
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
Trade Payables
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
Other Current Liabilities
1,093.62
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
Short Term Borrowings
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
Short Term Provisions
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
Total Liabilities
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
Net Block
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
Gross Block
15,735.87
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
Accumulated Depreciation
6,305.64
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
Non Current Assets
11,627.69
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
Capital Work in Progress
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
Non Current Investment
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
Long Term Loans & Adv.
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
971.75
857.53
Other Non Current Assets
74.03
77.61
166.82
255.71
210.06
176.54
168.88
158.89
162.09
46.80
Current Assets
13,209.51
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
Current Investments
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
Inventories
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
Sundry Debtors
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
Cash & Bank
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
Other Current Assets
1,407.05
442.02
415.53
480.20
1,226.01
1,223.17
858.67
630.63
468.31
622.17
Short Term Loans & Adv.
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
463.21
459.94
Net Current Assets
8,617.96
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
Total Assets
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
PBT
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
Adjustment
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
Changes in Working Capital
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
Cash after chg. in Working capital
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
Net Fixed Assets
-466.10
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
Net Investments
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
Others
612.35
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
Cash from Financing Activity
-1,329.90
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
Net Cash Inflow / Outflow
38.12
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
Opening Cash & Equivalents
742.38
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
Closing Cash & Equivalent
793.29
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
ROA
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
ROE
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
ROCE
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
Fixed Asset Turnover
1.84
1.89
1.79
1.25
1.36
1.40
1.26
1.47
1.69
1.61
Receivable days
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
Inventory Days
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
Payable days
54.19
57.55
59.02
57.37
46.96
51.51
52.17
44.93
48.58
50.51
Cash Conversion Cycle
51.73
52.66
57.47
101.50
106.05
106.55
112.14
107.41
113.72
123.59
Total Debt/Equity
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
Interest Cover
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76

News Update:


  • Cipla launches 'Spirofy' on World COPD Day
    17th Nov 2021, 09:05 AM

    With this launch, the company intends to revolutionize Obstructive Airway Disease diagnosis

    Read More
  • Cipla selected in S&P Dow Jones Sustainability Index for Emerging Markets for 2021
    16th Nov 2021, 09:58 AM

    The DJSI family of indices is operated by one of the world's leading index providers S&P Dow Jones

    Read More
  • Cipla reports 7% rise in Q2 consolidated net profit
    27th Oct 2021, 12:36 PM

    Total consolidated income of the company increased by 9.60% at Rs 5,580.47 crore for Q2FY22

    Read More
  • Cipla - Quarterly Results
    26th Oct 2021, 18:38 PM

    Read More
  • Cipla, Eli Lilly and Company enter into strategic partnership in India
    4th Oct 2021, 11:41 AM

    Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products -- Humalog & Trulicity to Cipla, subject to all regulatory approvals

    Read More
  • Cipla subscribes 5% stake in Swasth Digital Health Foundation
    20th Sep 2021, 12:25 PM

    The company aims to leverage digital technologies and build healthcare tech infrastructure

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.